HealthCap
VC Fund
Stockholm, Sweden
HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with the Odlander Fredrikson Group as their exclusive investments advisor. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized provider of venture capital within life sciences Europe.
- Total investments:
- 133
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $209M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries HealthCap invests in
Stages HealthCap invests in
Countries HealthCap invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5.7M–$85M
- Series B
- $12M–$92M
Investment Focus
Industry
- Biotechnology 59 (44%)
- Health Care 52 (39%)
- Medical 28 (21%)
- Therapeutics 25 (19%)
- Pharmaceutical 25 (19%)
Stage
- Series B 32 (24%)
- Series A 29 (22%)
- Funding Round 20 (15%)
- Series C 14 (11%)
- Series E 3 (2%)
Country
- United States 28 (21%)
- Sweden 19 (14%)
- France 6 (5%)
- Switzerland 5 (4%)
- Germany 4 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bjorn Odlander
Founder and Partner
|
Founder and Partner | Total investments: 1 | Find email | |
Marten Steen
Partner
|
Partner | Total investments: 12 | Find email | |
Per Samuelsson
Partner
|
Partner | Total investments: 3 | Find email | |
Anki Forsberg
Partner
|
Partner | Total investments: 0 | Find email | |
Carl Dalsgaard
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CurifyLabs
|
CurifyLabs develops technology for the automated compounding of personalized medicines used in pharmacies and hospitals. Its platform combines compounding hardware, software, validated excipient bases, integrated quality control, and digital documentation to support the preparation of non-sterile medications through standardized workflows. Thecompany also provides formulation libraries and tools that enable pharmacists to create and produce patient-specific dosage forms while maintaining traceability and consistency throughout the compounding process. Its solutions are used to support personalized medication preparation across a range of healthcare settings. | $13.7M / Series A / Jul 06, 2026 | |
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M / Series C / Apr 14, 2026 | |
Vicore Pharma
|
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. | $48M / Post-IPO Equity / Nov 13, 2025 | |
Hemab
|
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $157M / Series C / Oct 27, 2025 | |
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $4.5M / Series B / Jul 22, 2025 | |
Oncorena
|
Oncorena treatment for renal cancer | $14M / Venture - Series Unknown / Jun 26, 2025 | |
Positrigo
|
Positrigo is a company dedicated to the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. | $8.5M / Jun 10, 2025 | |
Tribune Therapeutics
|
Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. | $24.7M / Series A / Mar 26, 2025 | |
HelloBetter
|
HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services. | $6.5M / Venture - Series Unknown / Mar 05, 2025 | |
|
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M / Series B / Nov 25, 2024 | |
| See all 133 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does HealthCap invest in?
HealthCap invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 133 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is HealthCap's check size?
HealthCap typically joins rounds of $5.7M–$85M at Series A and $12M–$92M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HealthCap participates in.
How do I contact HealthCap?
Public channels for HealthCap include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at HealthCap?
The team at HealthCap includes Bjorn Odlander (Founder and Partner), Marten Steen (Partner) and Per Samuelsson (Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
